Skip to main content
Caplight Logo









CREATE Medicines

CREATE Medicines

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://createmedicines.com/

Last Round

Series B

May 14, 2026

Total Funding Raised

$245M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

CREATE Medicines is a clinical-stage biotechnology company that develops mRNA-based in vivo cell therapies for the treatment of cancer, autoimmunity, and fibrosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

mRNA immunotherapyin vivo CAR-Tlipid nanoparticleLNPcell programmingimmuno-oncologyin vivo cell therapymRNA deliverysolid tumor therapyhepatocellular carcinomaHCCnext-gen CAR-Toff-the-shelf cell therapybiotech platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CREATE Medicines Comparables

Compare CREATE Medicines with similar companies based on industry and business-model similarity.

CREATE Medicines comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Stylus Medicine
86%
Aera Therapeutics
85%
Alaya.bio
84%

CREATE Medicines Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 14, 2026
Series A ExtensionMay 18, 2023
Series AJan 6, 2021

Key People

Founding team and executive leadership

Jerome Chal

Chief Technology Officer

Executive Team

Brett Kaplan

Chief Business Officer and Chief Financial Officer

Executive Team

CREATE Medicines Investors

Notable investors and investment history

CREATE Medicines investors
InvestorRounds
Newpath PartnersSeries B, Series A, Series A Extension
ARCH Venture PartnersSeries A Extension, Series B
Hatteras Venture PartnersSeries A, Series B, Series A Extension
Moore Strategic VenturesSeries A Extension
ARCH Venture PartnersSeries A Extension
Alexandria Venture InvestmentsSeries B, Series A Extension, Series A
Hatteras Investment PartnersSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 29, 2026

    Monthly visitors increased 92% MoM.

  • Jul 27, 2026

    Grew 19% QoQ, from 37 to 44 employees.

CREATE Medicines Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CREATE Medicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CREATE Medicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range44
Year Founded2019
Last FundingMay 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?